---
schema_version: "secwatch.filing_event.v1"
accession: "0001549084-22-000075"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:33:20.977393+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics acquires Parker HMC business for $10M, appoints Scott Davis as CEO

## Summary
- Acquired Parker Hannifin's Human Motion and Control business for $10M ($5M cash + $5M zero-coupon note payable quarterly over 4 years).
- Acquisition includes Indego lower-limb exoskeleton line, expanding Ekso's product portfolio into home and community use markets.
- Steven Sherman resigned as CEO; appointed Scott G. Davis (formerly President/COO) as CEO effective immediately.
- Sherman remains Chairman and becomes Executive Chair under a one-year employment agreement with $125k salary and RSU grant.
- Adds Vanderbilt University as a key commercial and research partner to support future product development.

## SEC filing metadata
- accession: 0001549084-22-000075
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000075/0001549084-22-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000075/ekso-20221205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549084-22-000075
- JSON: https://secwatch.observer/filing/0001549084-22-000075.json
- Plain text: https://secwatch.observer/filing/0001549084-22-000075.txt

## Key facts
- Executive change
  Steven Sherman was appointed as Executive Chair at EKSO BIONICS HOLDINGS, INC..
  - Action: appointed
  - Role: Executive Chair
  source text: Mr. Sherman will continue to serve as Chair of the Board and will begin serving as Executive Chair of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000075/0001549084-22-000075-index.htm
- Executive change
  Scott G. Davis was appointed as Chief Executive Officer and Principal Executive Officer at EKSO BIONICS HOLDINGS, INC..
  - Action: appointed
  - Role: Chief Executive Officer and Principal Executive Officer
  source text: (ii) the Board appointed Scott G. Davis as Chief Executive Officer and Principal Executive Officer of the Company, each effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000075/0001549084-22-000075-index.htm
- Executive change
  Steven Sherman resigned as Chief Executive Officer at EKSO BIONICS HOLDINGS, INC..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On December 4, 2022, in connection with the closing of the Acquisition, (i) Steven Sherman, the Company’s Chief Executive Officer and Chair of the Company’s board of directors (the “Board”), resigned as the Company’s Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000075/0001549084-22-000075-index.htm
- M&A Transactions
  EKSO BIONICS HOLDINGS, INC. completed an acquisition involving Parker Hannifin Corporation for $10 million (closed 2022-12-05).
  - Action: acquisition
  - Counterparty: Parker Hannifin Corporation
  - Consideration: $10 million
  - Closing: 2022-12-05
  source text: partner to help power new product development. Ekso Bionics acquired all of Parker’s HMC global business assets in the U.S. and Europe for an aggregate purchase price of $10 million. Ekso paid $5 million at closing and delivered a $5 million subordinated, unsecured zero coupon note payable quarterly over four years, commencing December 31, 2023. “We are
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000075/0001549084-22-000075-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.